Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Maze Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Maze Therapeutics's regulatory disclosures and financial reporting.
Maze Therapeutics reported widening operating losses as it advances clinical programs while strengthening its balance sheet through an IPO and earlier licensing deals. For the quarter ended June 30, 2025 the company recorded a net loss of $33.7 million and a six‑month loss of $66.5 million, driven by higher research and development and public‑company costs. Research and development expense rose to $28.1 million for the quarter from $19.5 million a year earlier, reflecting clinical and manufacturing progression of lead programs.
The company completed an initial public offering that generated net proceeds of approximately $127.8 million, and held $264.5 million in cash and cash equivalents as of June 30, 2025, which management says is sufficient to fund operations for at least one year. In 2024 Maze recognized $165.0 million of license revenue from three agreements, including a $150.0 million upfront from Shionogi. The balance sheet now reflects elimination of redeemable convertible preferred stock after conversion to common shares. Overall, Maze is a clinical‑stage biotech investing heavily in R&D with one year of disclosed liquidity and no product revenue from sales.
Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.